SCHEMBL2179895

SCHEMBL2179895

COc1ccc(S(=O)(=O)Nc2ccc(-c3ccc4c(c3)CN([C@H](C(=O)O)C(C)C)C4=O)cc2)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRF1 P14222 1/20 0.49
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
PLAU P00749 1/20 0.46
CA12 O43570 1/20 0.46
CA9 Q16790 1/20 0.46
QPCT Q16769 1/20 0.45
QPCTL Q9NXS2 1/20 0.45
LMNA P02545 2/20 0.45
HTT P42858 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
GAA P10253 2/20 0.45
ATM Q13315 1/20 0.45
ALDH1A1 P00352 2/20 0.44
MAPT P10636 1/20 0.43
HDAC4 P56524 2/20 0.43
HDAC1 Q13547 2/20 0.43
ALOX15 P16050 1/20 0.42
MAPK1 P28482 1/20 0.42
HDAC3 O15379 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2179842 1.00 PRF1 (0.49) PRF1MEN1KMT2APLAUCA12
SCHEMBL2178321 0.93 MEN1 (0.47) PRF1MEN1KMT2APLAUCA12
SCHEMBL2180411 0.93 MEN1 (0.47) PRF1MEN1KMT2APLAUCA12
SCHEMBL2179996 0.90 LMNA (0.51) PRF1PLAULMNAATMSDCBP
SCHEMBL2181809 0.90 LMNA (0.51) PRF1PLAULMNAATMSDCBP
SCHEMBL2180412 0.86 PRF1 (0.48) PRF1MEN1KMT2ALMNAHTT
SCHEMBL2178685 0.86 PRF1 (0.48) PRF1MEN1KMT2ALMNAHTT
SCHEMBL2177958 0.83 MMP13 (0.47) PRF1LMNAHDAC4HDAC1HDAC3
SCHEMBL2177497 0.83 PRF1 (0.49) PRF1SDCBPSDC2
SCHEMBL2179727 0.83 MMP13 (0.47) PRF1LMNAHDAC4HDAC1HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT PRF1 4578/4885MEN1 3071/4885KMT2A 1705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.